Oxycodone
Post-Operative Pain, Non-Human Animal
Explore 23 assets in Post-Operative Pain, Non-Human Animal →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Medical University of Silesia
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Post-Operative Pain, Non-Human Animal
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Oxycodone (this asset) | Medical University of Silesia | Approved | BB · 64 |
| Lidocaine | Instituto Mexicano del Seguro Social | P4 | BBB |
| Ropivacaine | Tianjin Medical University General Hospital | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Tanta University | P4 | BBB |
| Nepenthe | IVO JURISIC | P4 | BBB |
| Marcaine | The Second Affiliated Hospital of Chongqing Medical University | P4 | BB |
| Fentanyl | IVO JURISIC | P4 | BB |
| Dexasone | IVO JURISIC | P4 | BB |
| Metamizole | Hospital dos Lusíadas | P4 | BB |
+30 more in the Post-Operative Pain, Non-Human Animal cohort
Other indications for Oxycodone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Vertebral Column Disorder | — | P4 | BBB · 73 |
| Osteoarthritis | — | P4 | BBB · 73 |
| Chronic Pain Syndrome | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Oxycodone in Post-Operative Pain, Non-Human Animal. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/oxycodone-post-operative-pain-non-human-animal
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →